JAMA:GWAS在欧洲人群发现 TLR1与H.pylori血清学阳性率相关

2013-05-10 高晓方 编译 中国医学论坛报

    欧洲一项研究通过全基因组关联分析(GWAS)及荟萃分析,确认Toll样受体(TLR)1与幽门螺杆菌(H.pylori)抗体血清学阳性率具有相关性,TLR1遗传变异或将有助于解释不同个体H.pylori感染风险的变化。论文本周发表于《美国医学会杂志》。   本研究在欧洲人群研究队列中[SHIP(n=3830)和RS-Ⅰ、Ⅱ(n=7108)]实施了2项独立GWAS,再行荟萃分析;

TLR1与H.pylori血清学阳性率相关


 

  欧洲一项研究通过全基因组关联分析(GWAS)及荟萃分析,确认Toll样受体(TLR)1与幽门螺杆菌(H.pylori)抗体血清学阳性率具有相关性,TLR1遗传变异或将有助于解释不同个体H.pylori感染风险的变化。论文本周发表于《美国医学会杂志》。

  本研究在欧洲人群研究队列中[SHIP(n=3830)和RS-Ⅰ、Ⅱ(n=7108)]实施了2项独立GWAS,再行荟萃分析;在RS-Ⅲ和SHIP-TREND人群中,分析全血RNA基因表达谱;在SHIP-TREND人群中,分析粪便H.pylori抗原。

  结果显示,在10938受试者中,56.2%为H.pylori血清学阳性。GWAS确认,TLR基因座(4p14;rs10004195;OR 0.70)和FCGR2A基因座(1q23.3;rs368433;OR 0.73)与H.pylori血清学阳性率具有相关性。在位于4p14的3个TLR基因中,仅TLR1存在rs10004195-A次要等位基因每拷贝数差异表达(β=-0.23)。粪便H.pylori抗原滴度较高的个体同样表现为最高四分位TLR1表达。此外,TLR1在胞外域表现出与rs10004195 SNP密切关联的Asn248Ser替换。

  ■ 同期述评

  GWAS时代的H.pylori易感性

  英国阿柏丁大学(Aberdeen University) 艾尔奥马(El-Omar)

  H.pylori感染仍有诸多基础问题有待解答,例如,感染在人与人间传播的准确机制仍不清楚,为何一些个体虽经充分感染暴露但却无细菌定植。

  本期JAMA中,迈勒(Maylerle)等报道了迄今首个也是最佳的GWAS研究,旨在揭示H.pylori易感性的遗传学背景。

  此项研究提供了重要的新资料。概括而言,TLR1(一种先天免疫应答蛋白受体)低表达与H.pylori感染的防护相关,而高表达则与H.pylori血清学阳性及粪便抗原载量升高可能相关。基于这些发现,过多TLR1似乎是不利的,其增加了暴露后获得或感染持续的可能性,尽管具体机制尚不清楚。

  TLR1已知是TLR2的辅助受体,二者形成异二聚体,可被来源于革兰阴性菌细胞壁的脂肽所识别。这一脂肽识别以及后续的免疫级联,可能形成一个抗炎环境,钝化宿主对病原体的炎症反应,以便利于细菌的定植。

  需要注意的是,此项研究仅评估了与H.pylori血清学阳性(当前或既往感染的证据)的相关性,未对定植或症状性疾病加以探讨。在H.pylori感染研究中存在的一个问题是,对H.pylori的暴露未能被确认,尤其是在感染压力较低的西方人群中。因此,在德国或荷兰的H.pylori血清学阴性,可能是因为缺乏暴露而非真正的遗传防护。因而,在解释本研究结果时,必须谨慎。

  本研究的结果,不但需要在欧洲人群中加以验证,也需要在其他族裔中验证,特别是在亚洲、东欧和南美等胃癌高发人群。通过国际性多中心协作研究,进一步阐明H.pylori易感性的遗传学基础,也非常必要。


Identification of Genetic Loci Associated With Helicobacter pylori Serologic Status
Importance 
Helicobacter pylori is a major cause of gastritis and gastroduodenal ulcer disease and can cause cancer. H pylori prevalence is as high as 90% in some developing countries but 10% of a given population is never colonized, regardless of exposure. Genetic factors are hypothesized to confer H pylori susceptibility.
Objective 
To identify genetic loci associated with H pylori seroprevalence in 2 independent population-based cohorts and to determine their putative pathophysiological role by whole-blood RNA gene expression profiling.
Design, Setting, and Participants 
Two independent genome-wide association studies (GWASs) and a subsequent meta-analysis were conducted for anti-H pylori IgG serology in the Study of Health in Pomerania (SHIP) (recruitment, 1997-2001 [n  = 3830]) as well as the Rotterdam Study (RS-I) (recruitment, 1990-1993) and RS-II (recruitment, 2000-2001 [n = 7108]) populations. Whole-blood RNA gene expression profiles were analyzed in RS-III (recruitment, 2006-2008 [n = 762]) and SHIP-TREND (recruitment, 2008-2012 [n = 991]), and fecal H pylori antigen in SHIP-TREND (n = 961).
Main Outcomes and Measures 
H pylori seroprevalence.
Results 
Of 10 938 participants, 6160 (56.3%) were seropositive for H pylori. GWASs identified the toll-like receptor (TLR) locus (4p14; top-ranked single-nucleotide polymorphism (SNP), rs10004195; P = 1.4 × 10−18; odds ratio, 0.70 [95% CI, 0.65 to 0.76]) and the FCGR2A locus (1q23.3; top-ranked SNP, rs368433; P = 2.1 × 10−8; odds ratio, 0.73 [95% CI, 0.65 to 0.81]) as associated with H pylori seroprevalence. Among the 3 TLR genes at 4p14, only TLR1 was differentially expressed per copy number of the minor rs10004195-A allele (β = −0.23 [95% CI, −0.34 to −0.11]; P = 2.1 × 10−4). Individuals with high fecal H pylori antigen titers (optical density >1) also exhibited the highest 25% of TLR1 expression levels (P = .01 by χ2 test). Furthermore, TLR1 exhibited an Asn248Ser substitution in the extracellular domain strongly linked to the rs10004195 SNP.
Conclusions and Relevance 
GWAS meta-analysis identified an association between TLR1 and H pylori seroprevalence, a finding that requires replication in nonwhite populations. If confirmed, genetic variations in TLR1 may help explain some of the observed variation in individual risk for H pylori infection.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1746594, encodeId=62af1e4659436, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 14 22:48:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280025, encodeId=d97e12800259e, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338889, encodeId=ebb31338889fe, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468945, encodeId=ca76146894526, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595559, encodeId=634815955596e, content=<a href='/topic/show?id=24f61492635' target=_blank style='color:#2F92EE;'>#pylori#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14926, encryptionId=24f61492635, topicName=pylori)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=361618256987, createdName=zhanglin3085, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=)]
    2013-10-14 智智灵药
  2. [GetPortalCommentsPageByObjectIdResponse(id=1746594, encodeId=62af1e4659436, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 14 22:48:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280025, encodeId=d97e12800259e, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338889, encodeId=ebb31338889fe, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468945, encodeId=ca76146894526, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595559, encodeId=634815955596e, content=<a href='/topic/show?id=24f61492635' target=_blank style='color:#2F92EE;'>#pylori#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14926, encryptionId=24f61492635, topicName=pylori)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=361618256987, createdName=zhanglin3085, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=)]
    2013-05-12 lxg951
  3. [GetPortalCommentsPageByObjectIdResponse(id=1746594, encodeId=62af1e4659436, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 14 22:48:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280025, encodeId=d97e12800259e, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338889, encodeId=ebb31338889fe, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468945, encodeId=ca76146894526, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595559, encodeId=634815955596e, content=<a href='/topic/show?id=24f61492635' target=_blank style='color:#2F92EE;'>#pylori#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14926, encryptionId=24f61492635, topicName=pylori)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=361618256987, createdName=zhanglin3085, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1746594, encodeId=62af1e4659436, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 14 22:48:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280025, encodeId=d97e12800259e, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338889, encodeId=ebb31338889fe, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468945, encodeId=ca76146894526, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595559, encodeId=634815955596e, content=<a href='/topic/show?id=24f61492635' target=_blank style='color:#2F92EE;'>#pylori#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14926, encryptionId=24f61492635, topicName=pylori)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=361618256987, createdName=zhanglin3085, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1746594, encodeId=62af1e4659436, content=<a href='/topic/show?id=989d1e525e5' target=_blank style='color:#2F92EE;'>#TLR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17525, encryptionId=989d1e525e5, topicName=TLR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Oct 14 22:48:00 CST 2013, time=2013-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1280025, encodeId=d97e12800259e, content=<a href='/topic/show?id=b05983454a' target=_blank style='color:#2F92EE;'>#GWAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8345, encryptionId=b05983454a, topicName=GWAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338889, encodeId=ebb31338889fe, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468945, encodeId=ca76146894526, content=<a href='/topic/show?id=52f089381e5' target=_blank style='color:#2F92EE;'>#血清学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89381, encryptionId=52f089381e5, topicName=血清学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43126964261, createdName=jjjiang0201, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595559, encodeId=634815955596e, content=<a href='/topic/show?id=24f61492635' target=_blank style='color:#2F92EE;'>#pylori#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14926, encryptionId=24f61492635, topicName=pylori)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=361618256987, createdName=zhanglin3085, createdTime=Sun May 12 01:48:00 CST 2013, time=2013-05-12, status=1, ipAttribution=)]

相关资讯

Nature:幽门螺旋杆菌的致命弱点

        来自美国能源部(DOE)SLAC国家加速实验室的科学家们在实验中揭示了攻击一种常见胃部细菌——幽门螺旋杆菌(Helicobacter pylori)的潜在新途径,这种细菌可以引起溃疡,并可显著提高形成胃癌的几率。相关论文发表在12月9日的《自然》(Nature)杂志上。      &n

Lancet:序贯疗法Hp根除率更高

       我国台湾幽门螺杆菌联盟公布的一项多中心、开放标签、随机研究显示,与标准三联抗幽门螺杆菌(Hp)治疗相比,序贯治疗的Hp根除率更高。因此,研究者认为,序贯疗法应成为Hp感染的标准一线治疗方案。文章于11月16日在线发表在《柳叶刀》杂志上。        该研究从台湾地区6个医疗中心纳入900例Hp感染

J Clin Invest:缺铁增强幽门螺杆菌的致癌作用

数据表明,缺铁可增强幽门螺旋杆菌毒力,它可作为一个可测定的生物标记,用来识别具有得胃癌高风险的感染者。 胃腺癌与幽门螺旋杆菌感染强相关,但大多数被感染的人不会得胃癌。幽门螺杆菌菌株包含胞嘧啶-腺嘌呤-鸟嘌呤致病基因组(CAG +),它可以编码CagA蛋白和IV型分泌系统(T4SS),从而引发更严重的疾病。幽门螺旋杆菌感染也与缺铁性贫血相关,这同样增强患胃癌危险。 为了定义在胃

Lancet:幽门螺杆菌的新疗法,杀菌率九成以上

  台大医院研究团队发现,清除导致多种胃病的“幽门螺杆菌”,采取两段式服药的“序列疗法”治疗效果,比传统的“三合一疗法”效果更好,杀菌率最高可到94%以上;这项研究不但改写幽门螺杆菌治疗准则,对于胃病的防治也有重要的贡献,有关研究成果已发表在今年11月份的国际顶尖医学期刊Lancet上。   由台大医院医疗团队率领的幽门螺杆菌大规模试验研究,共在台大、荣总、马偕、义大医院等6所医学中心收案900

GE:幽门螺杆菌表观遗传学层面调控胃癌发生

图1. 实验设计流程图 幽门螺杆菌感染为公认的胃癌发生的I类风险因子。幽门螺杆菌感染可以引起胃粘膜的慢性炎症、萎缩、肠上皮化生以及不典型增生,最终导致胃癌的发生。研究已证实根除幽门螺杆菌治疗可有效降低胃癌的发生率。然而幽门螺杆菌造成的基因层面的影响仍不十分清楚。基因以及表观遗传学机制在肿瘤发生过程中出现的分子、相关信号通路调控异常中发挥十分重要的作用。那么环境因素—幽门螺杆菌的感染是否会对患

Helicobacter:益生菌具抑制Hp感染能力

       目前治疗幽门螺杆菌感染的药物包括抗生素和质子泵抑制剂。来自中国台湾的研究研究人员们检测了乳酸杆菌抑制幽门螺杆菌感染的能力。相关文章发表在最新一期的《Helicobacter》杂志上。        该项试验对台湾健康志愿者的成人排泄物、婴儿排泄物、乳汁及阴道拭子进行了收集,并从这些样品中分离